Lexaria reports significant bioavailability results

Lexaria Bioscience (OTCQX: LXRP) (CSE: LXX) reported significant bioavailability results from its randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBDTM – a proprietary, DehydraTECH™ powered, cannabidiol (“CBD”) fortified hemp oil capsule developed by Lexaria. We understand the degree and speed of CBD absorption into blood plasma and potential cardiovascular and cognitive performance enhancement were outstanding both in its own right and in comparison to other published results available (read full news release here).

After 30 minutes, the TurboCBDTM delivered 317% more CBD to the bloodstream compared to the positive control; after 60 minutes there was more CBD delivered than at any time by the positive control and more CBD delivered by the control at every period in the study. In addition, THC was not detectible establishing the purity of the TurboCBDTM capsules. We have interviewed management and conclude these are exceptional results. It reminds us of the nicotine study LXRP published earlier this year. We also learned LXRP is in active discussions with several potential nicotine-based licensees and has had repeated calls with most of them.

We like the investor benefits that LXRP’s scientific studies are generating. There are “competitive” methods to improve bioavailability emerging but we have not seen any with the scientifically rigorous, clinical data being developed by LXRP. This will prove to be a significant advantage when agencies such as the U.S. Food and Drug Administration (FDA) and Health Canada ask for evidence to support the claimed benefits of medical cannabis products.

We have additional information that we will be summarizing in a more detailed report this week.

Lexaria Bioscience (OTCQX: LXRP) (CSE: LXX) had two significant announcements last week. In addition to the scientific results described above, LXRP and Hill Street Beverage Company Inc. (TSXV: BEER) jointly announced a Definitive Agreement to license Lexaria’s DehydraTECHTM, on a semi-exclusive basis, for a term of five years, to produce a line of cannabis-infused, alcohol-free beverages for Canadian distribution subject to regulatory approval (read full news release here).

We find this news important because it adds to the growing body of evidence that LXRP’s DehydraTECHTM platform has application in beverages. BEER produces award-winning alcohol-free wines and beverages. So the flavour masking properties of DehydraTECHTM was an important consideration in their decision.

Also, this is a license agreement that will add to LXRP’s revenue base in the future.

Whether it’s scientific studies or the practicality of new licensing agreements with end users, the evidence keeps mounting that LXRP’s DehydraTECHTM is establishing itself as the go-to technology for improved bioavailability. We think LXRP is getting closer to the point of making an agreement that will vault the company to the next higher level of corporate development and investment returns.